A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Solid Tumors
DRUG: Brivanib
Dose Limiting Toxicity, at the end of the first cycle of the study|Maximum Tolerated Dose, at the end of the first cycle of the study
To assess any preliminary evidence of anti-tumor activity observed with BMS-582664, at the end of the study
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.